T2 Biosystems, a company specializing in the rapid detection of sepsis-causing pathogens, announced on May 7, 2024, its intention to enter a strategic partnership with ECO Laboratory to advance the launch of the T2Lyme Panel, a diagnostic test for early Lyme disease. The non-binding letter of intent with ECO Laboratory, led by Lyme disease expert Karen Weeks, aims to establish the premier Lyme testing laboratory in the United States. The T2Lyme Panel, which is expected to be launched as a Laboratory Developed Test (LDT) in Q3 2024, offers a significant improvement over current two-tiered antibody tests, potentially detecting Lyme disease within the first 30 days after infection. T2 Biosystems is in the final stages of internal validation and verification of the T2Lyme Panel and will disclose further details upon the execution of a definitive agreement with ECO Laboratory.

T2 Biosystems, a company specializing in the rapid detection of sepsis-causing pathogens, announced on May 7, 2024, its intention to enter a strategic partnership with ECO Laboratory to advance the launch of the T2Lyme Panel, a diagnostic test for early Lyme disease. The non-binding letter of intent with ECO Laboratory, led by Lyme disease expert Karen Weeks, aims to establish the premier Lyme testing laboratory in the United States. The T2Lyme Panel, which is expected to be launched as a Laboratory Developed Test (LDT) in Q3 2024, offers a significant improvement over current two-tiered antibody tests, potentially detecting Lyme disease within the first 30 days after infection. T2 Biosystems is in the final stages of internal validation and verification of the T2Lyme Panel and will disclose further details upon the execution of a definitive agreement with ECO Laboratory.